4,123 Shares in Gilead Sciences, Inc. (GILD) Acquired by Parametrica Management Ltd
Parametrica Management Ltd acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 4,123 shares of the biopharmaceutical company’s stock, valued at approximately $295,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. Welch Investments LLC bought a new stake in Gilead Sciences in the 3rd quarter valued at $108,000. Wealthcare Advisory Partners LLC bought a new stake in Gilead Sciences in the 3rd quarter valued at $133,000. Horan Capital Advisors LLC. bought a new stake in Gilead Sciences in the 3rd quarter valued at $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Gilead Sciences in the 2nd quarter valued at $147,000. Finally, Hanson & Doremus Investment Management increased its holdings in Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 1,613 shares during the last quarter. Institutional investors own 76.97% of the company’s stock.
A number of analysts have issued reports on the stock. Barclays reiterated an “overweight” rating and issued a $95.00 price target (up from $90.00) on shares of Gilead Sciences in a report on Tuesday, March 6th. BidaskClub downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Royal Bank of Canada reiterated a “buy” rating and issued a $94.00 price target on shares of Gilead Sciences in a report on Friday, February 23rd. Finally, Leerink Swann reissued a “market perform” rating and issued a $80.00 price objective (down from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $87.75.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same period in the previous year, the company earned $2.70 EPS. The firm’s revenue for the quarter was down 18.7% compared to the same quarter last year. analysts predict that Gilead Sciences, Inc. will post 6.21 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be paid a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, March 15th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.82%. Gilead Sciences’s payout ratio is currently 59.77%.
In other Gilead Sciences news, Chairman John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $78.65, for a total value of $3,932,500.00. Following the completion of the sale, the chairman now directly owns 3,067,762 shares of the company’s stock, valued at approximately $241,279,481.30. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $78.69, for a total transaction of $1,967,250.00. Following the completion of the sale, the executive vice president now directly owns 69,426 shares of the company’s stock, valued at $5,463,131.94. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 424,435 shares of company stock valued at $33,602,330. 1.30% of the stock is owned by corporate insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.